Lipid-based nanoparticles as drug delivery carriers for cancer therapy

Front Oncol. 2024 Apr 10:14:1296091. doi: 10.3389/fonc.2024.1296091. eCollection 2024.

Abstract

Cancer is a severe disease that results in death in all countries of the world. A nano-based drug delivery approach is the best alternative, directly targeting cancer tumor cells with improved drug cellular uptake. Different types of nanoparticle-based drug carriers are advanced for the treatment of cancer, and to increase the therapeutic effectiveness and safety of cancer therapy, many substances have been looked into as drug carriers. Lipid-based nanoparticles (LBNPs) have significantly attracted interest recently. These natural biomolecules that alternate to other polymers are frequently recycled in medicine due to their amphipathic properties. Lipid nanoparticles typically provide a variety of benefits, including biocompatibility and biodegradability. This review covers different classes of LBNPs, including their characterization and different synthesis technologies. This review discusses the most significant advancements in lipid nanoparticle technology and their use in medicine administration. Moreover, the review also emphasized the applications of lipid nanoparticles that are used in different cancer treatment types.

Keywords: active targeting; cancer therapy; drug delivery; lipid-based nanoparticles; nanomedicine; passive targeting.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Research Fund for Innovation Chinese Medicine of The Hong Kong Polytechnic University (E-ABCT-BBBB-2).